Atrial Fibrillation

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 512-522

  Nattel, Stanley ^a,b   Ehrlich, Joachim R ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4844228938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50059-2     Document Type: Chapter

References (73)

1. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 1996, 131:790-795.
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998, 98:946-952.
3. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998, 158:229-234.
4. Nattel S New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226.
5. Sopher SM, Camm AJ Atrial fibrillation: Maintenance of sinus rhythm versus rate control. Am J Cardiol 1996, 77:24A-37A.
6. Sakata K, Kurihara H, Iwamori K, et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am J Cardiol 1997, 80:1522-1527.
7. Ehrlich JR, Nattel S, Hohnloser SH Atrial fibrillation and congestive heart failure: Specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002, 13:399-405.
8. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomittant clinical and hemodynamical changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998, 32:197-204.
9. Dries DL, Aarons D, Exner DV, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
10. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001, 104:292-296.
11. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002, 144:597-607.
12. Nattel S Therapeutic implications of atrial fibrillation mechanisms: Can mechanistic insights be used to improve AF management?. Cardiovasc Res 2002, 54:347-360.
13. Cox JL, Schuessler RB, Boineau JP The development of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000, 12:2-14.
14. Derakhchan K, Villemaire C, Talajic M, Nattel S The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. Cardiovasc Res 2001, 50:75-84.
15. Nattel S, Khairy P, Roy D, et al. New approaches to atrial fibrillation management: A critical review of a rapidly evolving field. Drugs 2002, 62:2377-2397.
16. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins. N Engl J Med 1998, 339:659-666.
17. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002, 105:1077-1081.
18. Wu TJ, Ong JJ, Chang CM, et al. Pulmonary veins and ligament of marshall as sources of rapid activations in a canine model of sustained atrial fibrillation. Circulation 2001, 103:1157-1163.
19. Berenfeld O, Zaitsev AV, Mironov SF, et al. Frequency-dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. Circ Res 2002, 90:1173-1180.
20. Schuessler RB, Grayson TM, Bromberg BI, et al. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 1992, 71:1254-1267.
21. Mandapati R, Skanes A, Chen J, et al. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000, 101:194-199.
22. Kneller J, Zou R, Vigmond EJ, et al. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res 2002, 90:E73-E87.
23. Derakhchan K, Li D, Courtemanche M, et al. Method for simultaneous epicardial and endocardial mapping of in vivo canine heart: Application to atrial conduction properties and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001, 12:548-555.
24. Katritsis D, Iliodromitis E, Fragakis N, et al. Ablation therapy of type I atrial flutter may eradicate paroxysmal atrial fibrillation. Am J Cardiol 1996, 78:345-347.
25. Liu TY, Tai CT, Chen SA Treatment of atrial fibrillation by catheter ablation of conduction gaps in the crista terminalis and cavotricuspid isthmus of the right atrium. J Cardiovasc Electrophysiol 2002, 13:1044-1046.
26. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995, 92:1954-1968.
27. Fareh S, Villemaire C, Nattel S Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced electrical remodeling. Circulation 1998, 98:2202-2209.
28. Franz MR, Karasik PL, Li C, et al. Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997, 30:1785-1792.
29. Manios EG, Kanoupakis EM, Chlouverakis GI, et al. Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: Relation with recurrence. Cardiovasc Res 2000, 47:244-253.
30. Sun H, Chartier D, Leblanc N, Nattel S Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001, 49:751-761.
31. Courtemanche M, Ramirez RJ, Nattel S Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. Am J Physiol 1998, 275:H301-H321.
32. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999, 84:776-784.
33. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997, 81:512-525.
34. + current in a chronic dog model of atrial fibrillation. Circ Res 1997, 81:1045-1052.
35. van der Velden HM, Ausma J, Rook MB, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000, 46:476-486.
36. Dobrev D, Graf E, Wettwer E, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: Decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 2001, 104:2551-2557.
37. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997, 96:3157-3163.
38. Sun H, Gaspo R, Leblanc N, Nattel S Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 1998, 98:719-727.
39. Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001, 103:691-698.
40. Hobbs WJ, Van Gelder IC, Fitzpatrick AP, et al. The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999, 10:866-870.
41. Chen YJ, Chen SA, Chen YC, et al. Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: Implication in initiation of atrial fibrillation. Circulation 2001, 104:2849-2854.
42. Li D, Fareh S, Leung TK, Nattel S Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different kind. Circulation 1999, 100:87-95.
43. Goette A, Lendeckel U, Klein HU Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002, 54:247-258.
44. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608-2614.
45. Li D, Melnyk P, Feng J, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000, 101:2631-2638.
46. Bosch RF, Nattel S Cellular electrophysiology of atrial fibrillation. Cardiovasc Res 2002, 54:259-269.
47. Chen YC, Chen SA, Chen YJ, et al. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol 2002, 39:366-372.
48. Sinno H, Derakhchan K, Libersan D, et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003, 107:1930-1936.
49. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003, 299:251-254.
50. Lai LP, Su MJ, Yeh HM, et al. Association of the human minK gene 38G allele with atrial fibrillation: Evidence of possible genetic control on the pathogenesis of atrial fibrillation. Am Heart J 2002, 144:485-490.
51. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003, 421:634-639.
52. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997, 29:709-715.
53. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998, 158:1316-1320.
54. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation)-Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231-1266.
55. Hart RG, Halperin JL Atrial fibrillation and stroke: Concepts and controversies. Stroke 2001, 32:803-808.
56. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 2002, 106:2854-2858.
57. Hart RG, Benavente O, McBride R, Pearce LA Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999, 131:492-501.
58. Wahlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002, 107:93-99.
59. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy-Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000, 35:183-187.
60. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
61. Wijffels MC, Dorland R, Mast F, Allessie MA Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000, 102:260-267.
62. Kneller J, Leon J, Nattel S How do class 1 antiarrhythmic drugs terminate atrial fibrillation? A quantitative analysis based on a realistic ionic model. Circulation 2001, 104:5.
63. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: A comparative, placebo controlled study. Heart 2000, 84:251-257.
64. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913-920.
65. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003, 107:1440-1446.
66. Nattel S Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998, 37:567-577.
67. Cox JL, Ad N, Palazzo T, et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000, 12:15-19.
68. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000, 102:2619-2628.
69. Skanes AC, Krahn AD, Yee R, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial of Physiologic Pacing-CTOPP Investigators. J Am Coll Cardiol 2001, 38:167-172.
70. Hohnloser SH, Kuck KH, Lilienthal J Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF)-A randomised trial. Lancet 2000, 356:1789-1794.
71. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
72. Fareh S, Benardeau A, Thibault B, Nattel S The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999, 100:2191-2197.
73. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C Trandopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction: TRACE Study group-TRAndolapril Cardiac Evaluation. Circulation 1999, 100:376-380.